|
1
|
Sonneveld P, Avet-Loiseau H, Lonial S,
Usmani S, Siegel D, Anderson KC, Chng WJ, Moreau P, Attal M, Kyle
RA, et al: Treatment of multiple myeloma with high-risk
cytogenetics: a consensus of the International Myeloma Working
Group. Blood. 127:2955–2962. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Abdi J, Chen G and Chang H: Erratum: Drug
resistance in multiple myeloma: Latest findings and new concepts on
molecular mechanisms. Oncotarget. 6:73642015.PubMed/NCBI
|
|
3
|
Mimura N, Hideshima T and Anderson KC:
Novel therapeutic strategies for multiple myeloma. Exp Hematol.
43:732–741. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Costa LJ, Brill IK, Omel J, Godby K, Kumar
SK and Brown EE: Recent trends in multiple myeloma incidence and
survival by age, race, and ethnicity in the United States. Blood
Adv. 1:282–287. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lionetti M, Biasiolo M, Agnelli L,
Todoerti K, Mosca L, Fabris S, Sales G, Deliliers GL, Bicciato S,
Lombardi L, et al: Identification of microRNA expression patterns
and definition of a microRNA/mRNA regulatory network in distinct
molecular groups of multiple myeloma. Blood. 114:e20–e26. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Calin GA and Croce CM: MicroRNAs and
chromosomal abnormalities in cancer cells. Oncogene. 25:6202–6210.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Calin GA and Croce CM: MicroRNA-cancer
connection: The beginning of a new tale. Cancer Res. 66:7390–7394.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Seckinger A, Meißner T, Moreaux J, Benes
V, Hillengass J, Castoldi M, Zimmermann J, Ho AD, Jauch A,
Goldschmidt H, et al: miRNAs in multiple myeloma-a survival
relevant complex regulator of gene expression. Oncotarget.
6:39165–39183. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Leotta M, Biamonte L, Raimondi L,
Ronchetti D, Di Martino MT, Botta C, Leone E, Pitari MR, Neri A,
Giordano A, et al: A p53-dependent tumor suppressor network is
induced by selective miR-125a-5p inhibition in multiple myeloma
cells. J Cell Physiol. 229:2106–2116. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chi J, Ballabio E, Chen XH, Kusec R,
Taylor S, Hay D, Tramonti D, Saunders NJ, Littlewood T, Pezzella F,
et al: MicroRNA expression in multiple myeloma is associated with
genetic subtype, isotype and survival. Biol Direct. 6:232011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Luo X, Gu J, Zhu R, Feng M, Zhu X, Li Y
and Fei J: Integrative analysis of differential miRNA and
functional study of miR-21 by seed-targeting inhibition in multiple
myeloma cells in response to berberine. BMC Syst Biol. 8:822014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Esquela-Kerscher A: The lin-4 microRNA:
The ultimate micromanager. Cell Cycle. 13:1060–1061. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Iorio MV and Croce CM: microRNA
involvement in human cancer. Carcinogenesis. 33:1126–1133. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Garzon R and Marcucci G: Potential of
microRNAs for cancer diagnostics, prognostication and therapy. Curr
Opin Oncol. 24:655–659. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ma Q, Chen Z, Jia G, Lu X, Xie X and Jin
W: The histone demethylase PHF8 promotes prostate cancer cell
growth by activating the oncomiR miR-125b. Onco Targets Ther.
8:1979–1988. 2015.PubMed/NCBI
|
|
16
|
Yu X, Shi W, Zhang Y, Wang X, Sun S, Song
Z, Liu M, Zeng Q, Cui S and Qu X: CXCL12/CXCR4 axis induced
miR-125b promotes invasion and confers 5-fluorouracil resistance
through enhancing autophagy in colorectal cancer. Sci Rep.
7:422262017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wong TN and Link DC: miR-125b
promotes leukemogenesis via VEGFA. Blood. 129:1409–1410.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang Q, Wang Y, Lu X, Zhao Z, Zhu L, Chen
S, Wu Q, Chen C and Wang Z: MiR-125b regulates
epithelial-mesenchymal transition via targeting Sema4C in
paclitaxel-resistant breast cancer cells. Oncotarget. 6:3268–3279.
2015.PubMed/NCBI
|
|
19
|
Zhang Y and Huang S: Up-regulation of
miR-125b reverses epithelial-mesenchymal transition in
paclitaxel-resistant lung cancer cells. Biol Chem. 2015. View Article : Google Scholar
|
|
20
|
Luo M, Tan X, Mu L, Luo Y, Li R, Deng X,
Chen N, Ren M, Li Y, Wang L, et al: MiRNA-21 mediates the
antiangiogenic activity of metformin through targeting PTEN and
SMAD7 expression and PI3K/AKT pathway. Sci Rep. 7:434272017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu MH, Yang L, Liu XJ, Nie ZY and Luo JM:
Targeted suppression of miRNA-21 inhibit K562 cells growth through
PTEN-PI3K/AKT signaling pathway. Zhonghua Xue Ye Xue Za Zhi.
37:982–986. 2016.(In Chinese). PubMed/NCBI
|
|
22
|
Yang X, Cheng Y, Li P, Tao J, Deng X,
Zhang X, Gu M, Lu Q and Yin C: A lentiviral sponge for miRNA-21
diminishes aerobic glycolysis in bladder cancer T24 cells via the
PTEN/PI3K/AKT/mTOR axis. Tumour Biol. 36:383–391. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang F, Li L, Chen Z, Zhu M and Gu Y:
MicroRNA-214 acts as a potential oncogene in breast cancer by
targeting the PTEN-PI3K/Akt signaling pathway. Int J Mol Med.
37:1421–1428. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Anderson KC: Progress and paradigms in
multiple myeloma. Clin Cancer Res. 22:5419–5427. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bates SE: Multiple myeloma: Multiplying
therapies. Clin Cancer Res. 22:54182016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gasparri ML, Casorelli A, Bardhi E,
Besharat AR, Savone D, Ruscito I, Farooqi AA, Papadia A, Mueller
MD, Ferretti E, et al: Beyond circulating microRNA biomarkers:
Urinary microRNAs in ovarian and breast cancer. Tumour Biol.
39:10104283176955252017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zeng Z, Chen X, Zhu D, Luo Z and Yang M:
Low expression of circulating MicroRNA-34c is associated with poor
prognosis in triple-negative breast cancer. Yonsei Med J.
58:697–702. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jiang X, Wang W, Yang Y, Du L, Yang X,
Wang L, Zheng G, Duan W, Wang R, Zhang X, et al: Identification of
circulating microRNA signatures as potential noninvasive biomarkers
for prediction and prognosis of lymph node metastasis in gastric
cancer. Oncotarget. 8:65132–65142. 2017.PubMed/NCBI
|
|
30
|
Qu X, Zhao M, Wu S, Yu W, Xu J, Xu J, Li J
and Chen L: Circulating microRNA 483-5p as a novel biomarker for
diagnosis survival prediction in multiple myeloma. Med Oncol.
31:2192014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Huang JJ, Yu J, LiJ Y, Liu YT and Zhong
RQ: Circulating microRNA expression is associated with genetic
subtype and survival of multiple myeloma. Med Oncol. 29:2402–2408.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li LN, Xiao T, Yi HM, Zheng Z, Qu JQ,
Huang W, Ye X, Yi H, Lu SS, Li XH and Xiao ZQ: MiR-125b increases
nasopharyngeal carcinoma radioresistance by targeting A20/NF-κB
signaling pathway. Mol Cancer Ther. 16:2094–2106. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shen Y, Xu H, Pan X, Wu W, Wang H, Yan L,
Zhang M, Liu X, Xia S and Shao Q: miR-34a and miR-125b are
upregulated in peripheral blood mononuclear cells from patients
with type 2 diabetes mellitus. Exp Ther Med. 14:5589–5596.
2017.PubMed/NCBI
|
|
34
|
Piatopoulou D, Avgeris M, Marmarinos A,
Xagorari M, Baka M, Doganis D, Kossiva L, Scorilas A and Gourgiotis
D: miR-125b predicts childhood acute lymphoblastic leukaemia poor
response to BFM chemotherapy treatment. Br J Cancer. 117:801–812.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li LT, Jiang G, Chen Q and Zheng JN: Ki67
is a promising molecular target in the diagnosis of cancer
(review). Mol Med Rep. 11:1566–1572. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang Z, Fang S, Di Y, Ying W, Tan Y and Gu
W: Modulation of NF-κB/miR-21/PTEN pathway sensitizes non-small
cell lung cancer to cisplatin. PLoS One. 10:e01215472015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang Y, Zheng L, Ding Y, Li Q, Wang R,
Liu T, Sun Q, Yang H, Peng S, Wang W and Chen L: MiR-20a induces
cell radioresistance by activating the PTEN/PI3K/Akt signaling
pathway in hepatocellular carcinoma. Int J Radiat Oncol Biol Phys.
92:1132–1140. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Carnero A, Blanco-Aparicio C, Renner O,
Link W and Leal JF: The PTEN/PI3K/AKT signalling pathway in cancer,
therapeutic implications. Curr Cancer Drug Targets. 8:187–198.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Medema RH, Kops GJ, Bos JL and Burgering
BM: AFX-like forkhead transcription factors mediate cell-cycle
regulation by ras and PKB through p27kip1. Nature.
404:782–787. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Roy SK, Srivastava RK and Shankar S:
Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of
FOXO transcription factor, leading to cell cycle arrest and
apoptosis in pancreatic cancer. J Mol Signal. 5:102010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen JS, Wang Q, Fu XH, Huang XH, Chen XL,
Cao LQ, Chen LZ, Tan HX, Li W, Bi J and Zhang LJ: Involvement of
PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in
hepatocellular carcinoma: Association with MMP-9. Hepatol Res.
39:177–186. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wei XE, Zhang FY, Wang K, Zhang QX and
Rong LQ: Assembly of the FKBP51-PHLPP2-AKT signaling complex in
cerebral ischemia/reperfusion injury in rats. Brain Res.
1566:60–68. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Strotbek M, Schmid S, Sanchez-Gonzalez I,
Boerries M, Busch H and Olayioye MA: miR-181 elevates Akt signaling
by co-targeting PHLPP2 and INPP4B phosphatases in luminal breast
cancer. Int J Cancer. 140:2310–2320. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gao D, Xiao Z, Li HP, Han DH and Zhang YP:
The mechanism study of miR-125b in occurrence and progression of
multiple myeloma. Cancer Med. 7:134–145. 2018. View Article : Google Scholar : PubMed/NCBI
|
